On a per-share basis, the Milton, Ontario-based company said it had a loss of 48 cents.
Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Aralez does expect things to pick up in 2017 though and said it was forecasting net revenues of between US$80mln and US$100mln, while it expects to report an underlying loss of between US$10mln and US$25mln. The company had a trading volume of 1,786,406 shares. Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) has declined 46.68% since August 8, 2016 and is downtrending. The share price has moved backward from its 20 days moving average -47.90% and negatively from its 50 days moving average -50.30%. By reviewing stock prices from the stock market history of the company and examining its analysts ratings can give an investment picture with updated information of stock which helps investors to make investing decision.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last released its earnings results on Monday, March 13th.
For the ongoing Fiscal Quarter, 1 analysts have an average earnings forecast of $-0.25 per share. These 1 Analysts are also projecting the mean revenue estimate of 30.5 Million. Aralez Pharmaceuticals had a negative return on equity of 65.67% and a negative net margin of 211.76%. The business's quarterly revenue was up 233.3% compared to the same quarter previous year. The low EPS estimate is $0.43, while the high EPS estimate is $0.49. The Stock now has the market capitalization of $155.5 Million, P/E (price to earnings ttm) of 0 and Weekly volatility of 20.13% and monthly volatility of 8.89% respectively. LLC increased its position in Aralez Pharmaceuticals by 30.3% in the third quarter. About 3.37 million shares traded or 287.47% up from the average.
In the past 5 years, the stock showed growth of -10.47% per annum. Integre Asset Management LLC raised its position in shares of Aralez Pharmaceuticals by 31.7% in the fourth quarter. Due to strong positive momentum, the stock ended at $2.37, which is also near the day's high of $2.63. Tiger Legatus Capital Management LLC now owns 1,985,000 shares of the company's stock valued at $8,754,000 after buying an additional 25,000 shares in the last quarter. The firm has "Buy" rating by Canaccord Genuity given on Tuesday, April 26.
In February 2016, Pozen merged with Tribute Pharmaceuticals Canada to create Aralez Pharmaceuticals, which added about a dozen drugs from Tribute to Pozen's Yosprala as well as Vimovo and Treximet, which are marketed by its partner. They acquire, develop and commercialize products primarily in cardiovascular, pain and other specialty areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine.